p-DARPP-32 (Thr 34) Antibody: sc-21601

DARPP-32 Background Information
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson’s disease and drug abuse. DARPP-32 is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on Thr 34 occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32 at Thr 34. Phosphorylated DARPP-32 at Thr 34 is a potent inhibitor of PP-1. Phosphorylation of DARPP-32 on Ser 137 by casein kinase inhibits the dephos-phorylation of Thr 34 by calcineurin. Phosphorylation of DARPP-32 on Thr 75 by CdK5 inhibits PKA by a competitive mechanism in vitro. Decreasing the phosphorylaton of DARPP-32 Thr 75 increases the dopamine-induced phosphorylation of PKA substrates.